NewsRoom Articles - BioMedWire (BMW)

TuesdayDec 23, 2025 10:00 am

New Approach Could Increase Response Rates for Cancer Immunotherapy

Immunotherapy, an approach that seeks to stimulate the immune system to attack and destroy cancer cells, is a new field of research that has shown remarkable results in some patients. However, the overall fraction of patients who can benefit from immunotherapy is still very low, and researchers have been looking for ways to make this treatment modality work for a lot more patients. Now, a team from Stanford University and MIT has developed a novel method through which the immune system can be primed to attack tumors in a way that could significantly improve response rates for more patients. For their study, the team focused on glycans, sugar molecules that exist on…

TuesdayDec 23, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline

OTLC’s Deciparticle(TM) platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current Preclinical PK data show that Sapu003, the intravenous Deciparticle(TM) formulation of Everolimus (Afinitor(R)), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering. Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new…

MondayDec 22, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study

Soligenix reported that SGX302 was well tolerated by all patients in cohort 3, with no drug-related adverse events identified during the treatment period. An optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application. SGX302 utilizes visible light-activated synthetic hypericin, a first-in-class photodynamic therapy mechanism. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation…

FridayDec 19, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing need for effective countermeasures. Ricin is a potent toxin capable of causing death within days of exposure because it stops protein synthesis inside cells, leading to organ failure. Soligenix has demonstrated meaningful preclinical efficacy for its ricin vaccine candidate. A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin…

FridayDec 19, 2025 9:00 am

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration. On Wednesday, the exclusion of a provision extending the ACA tax credits triggered a revolt within the GOP ranks as some moderates in their ranks joined Democrats in signing a discharge petition that would compel the House to conduct a vote on extending the tax credits for 3 years. However, none of the Republicans who signed this petition eventually voted against the…

ThursdayDec 18, 2025 10:00 am

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition. The study, conducted by a team at Beth Israel Medical Center and Harvard University analyzed blood samples taken from 140 individuals who never suffered from Covid, those who got infected…

WednesdayDec 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.…

TuesdayDec 16, 2025 10:00 am

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer. For a while, many researchers have been growing in conviction that the way cancer is treated needs to change from efforts geared at destroying cancer cells (through chemotherapy, surgery and radiation) to regarding cancer as a wound that needs to be helped to heal. This thinking was first…

MondayDec 15, 2025 9:45 am

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design. Six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20; evidence of accelerating regulatory momentum. Oncotelic Therapeutics’ OT-101 (Trabedersen) is the only TGF-β2-specific antisense in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates…

FridayDec 12, 2025 10:00 am

Study Highlights Increasing Cases of Breast Cancer in Younger Women

A study that involved an analysis of patient records in New York has discovered that breast cancer, and especially aggressive forms of this cancer, is occurring at a higher rate among younger women aged below 40. This group is currently regarded as low risk for breast cancer by the existing screening guidelines, and this calls for a review of those guidelines. The study analyzed data spanning 11 years taken from 2014 to the end of 2024. These outpatient records were taken from seven medical facilities that covered an area of approximately 200 miles in Western New York State. The team…